Pomona, New York — December 12, 2025 — NeuroLight, Inc., a neuromodulation company developing breakthrough technology aimed at the prevention and treatment of Alzheimer’s disease, other neurodegenerative diseases, PTSD, and sleep disorders, today announced a strategic corporate restructuring. The Company has formed three wholly owned subsidiaries—NeuroLight Therapeutics, LLC, NeuroLight Wellness, LLC, and NeuroLight Labs, LLC—to support its expanded mission of preventing and slowing neurodegenerative diseases while delivering immediate solutions for sleep improvement.
Supported by NSF/SBIR grants and a robust intellectual property portfolio, NeuroLight is now moving beyond its initial pilot studies to address high-impact medical and consumer markets in parallel.
A dual-path strategy: from wellness to therapeutics
While NeuroLight’s technology has immediate applications for insomnia and other sleep disturbances, the Company’s primary focus has expanded to include the prevention and slowing of Alzheimer’s disease (AD), the treatment of PTSD, and sleep-related pathologies associated with Parkinson’s disease and other non-AD dementias.
To navigate the distinct regulatory, commercial, and reimbursement environments of consumer wellness and medical devices, NeuroLight has established the following operating entities:
NeuroLight Therapeutics, LLC – This subsidiary is dedicated to the Company’s primary clinical mission. NeuroLight Therapeutics will lead FDA regulatory strategy and clinical trials focused on the prevention and slowing of Alzheimer’s disease and Mild Cognitive Impairment (MCI), the treatment of PTSD, and therapeutic interventions for sleep disturbances associated with Parkinson’s disease and other neurodegenerative conditions.
NeuroLight Wellness, LLC – This subsidiary is focused on the near-term commercialization of non-regulated consumer wellness products. NeuroLight Wellness will bring to market the NeuroMask™, a smart sleep mask that uses sensory brain stimulation via light and sound to improve sleep quality in the general population. This early market-entry strategy is designed to generate revenue, build brand awareness, and gather large-scale, real-world sleep data while therapeutic trials are underway.
NeuroLight Labs, LLC – This subsidiary is focused on the development and licensing of brain state optimization applications based on NeuroLight’s brain-state replication and engineering platform. Target applications include flow states, peak performance, accelerated learning, creativity, and emotional regulation in high-performance and enterprise environments.
The parent company, NeuroLight, Inc., will remain the core technology platform company, driving fundamental R&D, platform development, and a pipeline of future neuromodulation products and applications across all three subsidiaries.
“We are at a pivotal moment in the company’s history,” said Alexander Poltorak, Founder and President of NeuroLight. “By separating our operations into distinct subsidiaries, we can aggressively pursue the consumer market to help people sleep better today, while simultaneously dedicating the necessary resources to our long-term goal: using this technology to combat the progression of Alzheimer’s, support veterans and others living with PTSD, and address sleep-related pathologies in Parkinson’s and other neurodegenerative diseases.”
“This restructuring is fundamentally about aligning strategy, evidence, and execution,” said Dr. Jumaah Goldberg, Chief Strategy Officer of NeuroLight. “By pairing a wellness-first go-to-market pathway for NeuroMask with dedicated therapeutic development inside NeuroLight Therapeutics, we can shorten the time from lab insight to real-world impact, generate the longitudinal sleep and cognitive data that clinicians and regulators require, and structure partnerships and capital formation around clearly defined risk and value profiles.”